For the quarter ending 2026-03-31, SKYE had $2,266,517 increase in cash & cash equivalents over the period. -$8,557,917 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Amortization of debt discount | - | 0 | 0 | 0 |
| Change in estimate for legal contingencies | - | 0 | - | - |
| Gain from asset sale | - | 179,987 | 91,400 | 89,363 |
| Net loss | -12,509,361 | -14,441,963 | -12,754,660 | -28,728,191 |
| Write-down of vendor deposits | - | 0 | 0 | 0 |
| Depreciation and amortization | 172,886 | 180,009 | 178,898 | 364,445 |
| Stock-based compensation expense | 1,496,989 | 1,618,540 | 1,914,136 | 4,235,018 |
| Loss from disposal of assets | -7,615 | 0 | 0 | 0 |
| Change in estimate for legal contingency | - | - | 0 | - |
| Prepaid expenses | 396,781 | -3,207,421 | 2,448,499 | 1,061,850 |
| Right-of-use assets | 170,367 | - | - | - |
| Other current assets | -617,231 | -48,139 | 166,752 | -1,476,121 |
| Other assets | -18,001 | 0 | 0 | - |
| Accounts payable | 1,903,517 | -791,574 | -397,505 | 2,584,507 |
| Accrued interest related party-Related Party | - | 0 | 0 | 0 |
| Accrued interest related party-Nonrelated Party | - | 0 | 0 | 0 |
| Accrued payroll liabilities | -1,035,082 | 348,700 | 52,750 | -246,231 |
| Operating lease liability | -212,666 | -48,199 | -45,695 | -88,050 |
| Other current liabilities | 1,209,367 | 292,427 | 394,352 | 1,621,927 |
| Net cash used in operating activities | -8,557,917 | -9,766,487 | -13,364,375 | -19,931,667 |
| Proceeds from asset sales, net of legal expenses | - | 179,987 | 91,400 | 89,363 |
| Purchase of short-term investment | - | 2,983,494 | -7,875,810 | 24,747,039 |
| Maturities/(purchase) of short-term investments, net of maturities | -10,895,109 | - | - | - |
| Purchase of property and equipment | 0 | 0 | 0 | 6,312 |
| Cash from asset disposition | 850 | - | - | - |
| Net cash provided by (used in) investing activities | 10,895,959 | -2,803,507 | 7,967,210 | -24,663,988 |
| Proceeds from warrant exercises | - | 0 | - | - |
| Purchase under employee stock purchase plan | - | 11,413 | 0 | 18,158 |
| Proceeds from the issuance of common stock and warrants, net of equity issuance costs of 0 and 6,434,447, respectively | - | - | 0 | 0 |
| Proceeds from option exercises | - | 0 | - | - |
| Repayment of insurance premium loan payable | 71,525 | - | - | - |
| Net cash used in financing activities | -71,525 | 11,413 | 0 | 18,158 |
| Net increase (decrease) in cash and cash equivalents | 2,266,517 | -12,558,581 | -5,397,165 | -44,577,497 |
| Cash and cash equivalents, beginning of period | 5,882,498 | 18,441,079 | 68,415,741 | - |
| Cash and cash equivalents, end of period | 8,149,015 | 5,882,498 | 18,441,079 | - |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)